CoChat

The Future of Pain Management and Research: A Dose of Fatalism May Be Good for One's Health

Fraser, Jeffrey L · 2019 · Pain Medicine

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

My formula for greatness in a human being is ‘amor fati’: that one wants nothing to be different, not forward, not backward, not in all eternity. Not merely bear what is necessary, still less conceal it…but love it. —Friedrich Nietzsche The views on chronic pain expressed herein are those of a general neurologist with a skeptical turn of mind, who has practiced for 27 years at a large county hospital in the heart of Silicon Valley. While these views have a pessimistic aspect, I want to propose that new goals and new hopes often arise like a phoenix from the ashes of pessimism. Nietzsche’s philosophy likewise comprised a pessimistic element, but unlike the pessimism of Schopenhauer, Nietzsche’s pessimism was life-affirming. There still could be an altogether different kind of pessimism.… I call this pessimism of the future—for it comes! I see it coming! —Friedrich Nietzsche, on Dionysian pessimism, from The Gay Science Indeed, Nietzsche valued growth and self-overcoming above all else, and these life-affirming values, by definition, require opposing forces—namely, the pain and suffering of human existence, without which there can be no joy, no beauty, in self-overcoming. And life confided the secret to me: Behold, it said, I am that which must always overcome itself. —Friedrich Nietzsche, from Thus Spoke Zarathustra In the spirit of Dionysian pessimism, I would like to try to answer two questions: What are the reasons for pessimism with respect to the treatment of chronic pain? and By what means can patients, and their providers, subjugate this pessimism and engage in life-affirming growth and self-overcoming? For the purposes of this article, I will focus primarily on low back pain and sciatica, but the concerns raised herein apply to all forms of chronic pain seen in our neurology clinic. When management of back pain and sciatica fails to achieve satisfactory results, as is too often the case, the repeated frustration and disappointment are rendered all the more profound by the unrealistic expectations created by the medical–industrial complex in promoting various pharmacologic and invasive treatments. Data supporting medications and invasive interventions for back pain and sciatica are far from robust [1–4]. Moreover, the published reports of positive, “statistically significant” results in treatment trials continue to invite skeptical interpretation because of publication bias and other confounding factors [5]. Not least among these confounding factors is the influence of the drug and device manufacturers that sponsor the research, including their influence on study design [6]. Finally, we must remember that the concept of “statistical significance” has an inherently arbitrary aspect and that, in any case, statistical significance does not equal clinical significance. In spite of these caveats, low-value treatments continue to be overused, not just in the United States, but around the world [3]. Notwithstanding this sober assessment of pharmacologic and invasive treatments for low back pain and sciatica, the general public and the majority of practicing physicians have fallen victim to the overstated, sometimes fraudulent, claims of certain medical–industrial institutions. As the most obvious example, the role of the pharmaceutical industry in promoting the widespread overuse of opiates in the treatment of pain is well documented [7]. Along the same vein, we must recall the history of gabapentin, which initially was highly touted as a treatment for painful diabetic polyneuropathy. Pfizer, the maker of gabapentin, paid a $325M settlement for promoting the drug for off-label usages, despite the lack of scientific evidence. Nevertheless, that $325M investment has paid huge dividends: gabapentin remains by far the most commonly prescribed drug for a whole host of chronic pain problems, many of them ill-defined but often labeled as “neuropathic” to justify opening the special medicine cabinet reserved for this dreaded category of chronic pain. Based on published and unpublished studies, gabapentin’s role in treating painful diabetic polyneuropathy and chronic low back pain is dubious at best [8,9]. Likewise, its cousin, pregabalin, now appears largely ineffective for radicular pain [10]. In short, patients have been conditioned by our culture to expect too much from modern medicine. To quote Rudy Waltz, the narrator in Kurt Vonnegut’s “Deadeye Dick,” describing a local doctor in fictional Midland City, Ohio: “Dr. Mitchell was building a big practice on the principle that nobody in modern times should ever be the least uncomfortable or dissatisfied, since there were now pills for everything.” Unfortunately, front-line practitioners, caught between ingenuous patients and an often disingenuous medical–industrial complex, find it very difficult to offer a more honest perspective, even as this perspective is now substantiated in widely published guidelines. The truth can be very disappointing, and doctors do not w

Overview

Integrity signals

Registry

Crossref · 10.1093/pm/pnz047

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 2

  1. Feldman, UpToDate
  2. Chou, UpToDate

Cited by

See all 1

Metadata

Authors
Fraser, J. L.
Affiliations
Santa Clara Valley Medical Center (US)
Corresponding author
Fraser, Jeffrey L
Venue
Pain Medicine
Published
2019-03-19
Volume
20
Issue
9
Pages
1647-1650
ISSN
  • 1526-2375 (ISSN-L)
  • 1526-4637
OpenAlex
W2922860354
Cited by
1
References
25
Citations by year
2022: 1
FWCI
0.15
Type
journal article
Language
en
Open access
closed
Locations
  • Pain Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
chronic pain, low back pain, sciatica, pessimism, self-overcoming, medical-industrial complex, publication bias, pharmaceutical industry influence, treatment expectations, patient-provider relationship, pain management, Friedrich Nietzsche, placebo effect
MeSH terms
Humans, Pain Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.